Biomark Diagnostics Inc (BUX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 58 | 101 | 99 | 91 | 103 |
| Accounts receivable | 12 | 4 | -17 | -6 | 10 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | 5 |
| Other Working Capital | 17 | 67 | -231 | 62 | 15 |
| Other Operating Activity | -407 | -387 | -358 | -159 | -383 |
| Operating Cash Flow | $-321 | $-214 | $-506 | $-12 | $-250 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3 | -1 | -2 | -1 | 0 |
| Investing Cash Flow | $-3 | $-1 | $-2 | $-1 | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | -192 | 0 | -133 | 0 |
| Debt Repayment | -103 | -103 | -101 | -102 | -102 |
| Common Stock Issued | N/A | 0 | 1,542 | N/A | N/A |
| Other Financing Activity | 411 | 355 | -788 | 241 | 455 |
| Financing Cash Flow | $308 | $59 | $653 | $6 | $353 |
| Beginning Cash Position | 157 | 313 | 168 | 175 | 72 |
| End Cash Position | 141 | 157 | 313 | 168 | 175 |
| Net Cash Flow | $-15 | $-156 | $145 | $-7 | $103 |
| Free Cash Flow | |||||
| Operating Cash Flow | -321 | -214 | -506 | -12 | -250 |
| Capital Expenditure | -3 | -1 | -2 | N/A | N/A |
| Free Cash Flow | -323 | -216 | -509 | -12 | -250 |